Esteban Rodrigo Imedio

5PUBLICATIONS
17CO-AUTHORS
PharmacogenomicsMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Nov 19, 2024
Open-Label, Multicenter, Phase I Study to Assess Safety and Tolerability of Adavosertib Plus Durvalumab in Patients with Advanced Solid Tumors.

Manish R Patel, Gerald S Falchook, Judy S Wang

|Nov 02, 2024
Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial.

Erika P Hamilton, Gerald S Falchook, Judy S Wang

|Jun 06, 2023
A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors.

Todd M Bauer, Kathleen N Moore, Janet S Rader

|May 12, 2023
A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors.

Gerald S Falchook, Jasgit Sachdev, Esteban Rodrigo Imedio

|Oct 14, 2021
Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study.

Kathleen N Moore, Setsuko K Chambers, Erika P Hamilton

Pageof 1

Frequent Collaborators

5 joint publications

Suzanne Jones

2 joint publications

Kathleen N Moore

2 joint publications

Gerald S Falchook

2 joint publications

Erika P Hamilton